Time has come for immunotherapy in PTCL

Blood. 2014 May 15;123(20):3059-60. doi: 10.1182/blood-2014-04-565267.

Abstract

In this issue of Blood, Horwitz et al present encouraging results of a phase 2 study assessing the efficacy of the antibody-drug conjugate (ADC) brentuximab vedotin (BV) in relapsed/refractory peripheral T-cell lymphoma (PTCL).

Publication types

  • Comment

MeSH terms

  • Brentuximab Vedotin
  • Female
  • Humans
  • Immunoconjugates / therapeutic use*
  • Lymphoma, T-Cell / drug therapy*
  • Male
  • Neoplasm Recurrence, Local / drug therapy*

Substances

  • Immunoconjugates
  • Brentuximab Vedotin